Search company, investor...

United Biomedical


Unattributed VC - III | Alive

Total Raised


Last Raised

$18.02M | 2 yrs ago

About United Biomedical

United Biomedical operates as a biopharmaceutical company. The Company develops immunotherapeutics and vaccines for chronic and infectious diseases.

Headquarters Location

25 Davids Drive

Hauppauge, New York, 11788,

United States


Missing: United Biomedical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: United Biomedical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing United Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

United Biomedical is included in 3 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

United Biomedical Patents

United Biomedical has filed 19 patents.

The 3 most popular patent topics include:

  • Cognitive disorders
  • Dementia
  • Vaccines
patents chart

Application Date

Grant Date


Related Topics




G protein coupled receptors, Clusters of differentiation, Peptides, Peptide hormones


Application Date


Grant Date



Related Topics

G protein coupled receptors, Clusters of differentiation, Peptides, Peptide hormones



Latest United Biomedical News

FDA reviewing EUA request for Novavax COVID-19 vaccine

May 14, 2022

FDA reviewing EUA request for Novavax COVID-19 vaccine Staff writer, with CNA The Food and Drug Administration (FDA) yesterday said it was reviewing the technical data on the Novavax COVID-19 vaccine following the US drugmaker’s request for emergency use authorization (EUA). The request was filed several months ago, but the data provided at the time had been insufficient, containing only the vaccine’s processing information, FDA Director-General Wu Shou-mei (吳秀梅) said. The company recently provided the missing information by including data on the vaccine’s clinical trials, pharmacology and toxicology, Wu said, adding that health experts would assess the request once its review is complete. A vial and sryinge are pictured in front of the Novavax logo on Jan. 11 last year. Photo: Reuters The FDA aims to complete the review on the Novavax data within one month, she said. Novavax said in a statement on Friday that its submission includes data from two pivotal Phase 3 clinical trials, which enrolled about 30,000 participants aged 18 years or older in the US and Mexico. “In both trials, the vaccine demonstrated efficacy with a reassuring safety profile. Serious and severe adverse events were low in number, and balanced between vaccine and placebo groups,” Novavax said. The most common adverse reactions observed during the trials were headache, nausea or vomiting, myalgia, arthralgia, pain or tenderness at the injection site, fatigue and malaise, the company said. Taiwan has not yet received any doses of the Novavax vaccine, although the Central Epidemic Command Center in March said that the nation had ordered about 2 million doses through the global vaccine sharing initiative COVAX. Separately, commenting on Taiwan-based United Biomedical Inc (UBI) Asia’s reapplication for an EUA for its COVID-19 vaccine, Wu said the company has every right to do so, but it must provide new information and evidence before the review process can move forward. UBI Asia’s original EUA request was rejected on Aug. 16 last year after a measure of its UB-612 vaccine’s ability to neutralize SARS-CoV-2 failed to meet FDA standards. The company at the time said that it would present new findings to the FDA to have its EUA application reviewed again, which it did in March. Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

United Biomedical Frequently Asked Questions (FAQ)

  • Where is United Biomedical's headquarters?

    United Biomedical's headquarters is located at 25 Davids Drive, Hauppauge.

  • What is United Biomedical's latest funding round?

    United Biomedical's latest funding round is Unattributed VC - III.

  • How much did United Biomedical raise?

    United Biomedical raised a total of $33.54M.

  • Who are the investors of United Biomedical?

    Investors of United Biomedical include BOLD Capital Partners, Prime Movers Lab, Paycheck Protection Program, NYSTAR and Empire State Development.

  • Who are United Biomedical's competitors?

    Competitors of United Biomedical include ISA Pharmaceuticals, Immune Design, NextWave Pharmaceuticals, Xhale, Actinobac Biomed, BioCardia, Provepep, AI2, Beeologics, Nanomed Pharmaceuticals and 16 more.

Compare United Biomedical to Competitors

Banyan Biomarkers Logo
Banyan Biomarkers

Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

Valens Therapeutics

Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics


Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute ( and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Leuko Bioscience

Leuko Bioscience is aimed at treating diseases of the immune system

Orexo Logo

Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them.


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.